SEATTLE, WA–(Marketwired – Mar 1, 2017) – CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article and video interview discussing the innovative work of Vitality Biopharma (OTCQB: VBIO).

Vitality Biopharma is focused on the discovery and production of cannabinoid glycosides for the treatment of serious neurological and inflammatory diseases. Small molecule glycosylation alters the solubility and stability of drug compounds, and it could extend patent life, improve bioavailability, and reduce side effects through targeted drug delivery. Applying this prodrug technology to cannabinoids may increase their efficacy in treating numerous medical conditions.

In 2013, the company initiated a research program to develop efficient means of glycosylation through enzymatic biosynthesis. By late 2015 and early 2016, the company’s scientists applied this technology towards cannabinoids, including CBD and THC molecules, creating a new class of cannabinoid glycosides that it termed cannabosides. Since then, the company has filed patents covering over 20 cannabosides and started development on an inflammatory bowel disease (IBD) treatment.

According to Visiongain, the market for IBD treatments is expected to reach $9.3 billion by 2019, stimulated by rising disease incidence and non-invasive diagnosis, as well as technological advances in medicines.

Independent clinical trial data suggests that cannabis can induce remission even in patients that are resistant to steroids and biologic TNF-a inhibitors. In one eight-week placebo-controlled trial, there was a statistical change in the Crohn’s Disease Activity Index with cannabis use, and nearly half of patients entered into disease remission. In another study of cannabis use in IBD patients, there were improvements reported by 83.9% of patients for abdominal pain and 76.8% for abdominal cramping, which means that an overwhelming majority reported symptomatic improvement.

Currently, most cannabis therapies must be low-dose since THC is absorbed in the blood-brain barrier. Vitality believes that its prodrug cannabosides could enable targeted delivery of THC molecules into the gut, which would enable higher local concentrations for pain and inflammation in the gastrointestinal tract. The company plans to begin Phase I/II studies this year while taking pathways that involve shorter trials through acute dosing regimens.

In the video interview, Vitality Biopharma CEO Robert Brooke talks about cannabosides, IBD, Vitality’s federally-approved research facilities and practices, and the executive team.

Please follow the link to read the full article and see the interview: http://www.cannabisfn.com/vitality-biopharma-looks-improve-cannabinoid-compounds/

Learn how to become a CFN Media featured company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from your smart phone: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.